-
公开(公告)号：US20220016103A1
公开(公告)日：2022-01-20
申请号：US17376483
申请日：2021-07-15
申请人： Novartis AG
IPC分类号： A61K31/454 , A61K9/00 , A61P7/06
摘要： Described herein are methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with the Factor B inhibitor LNP023 or a pharmaceutically acceptable salt thereof, e.g. LNP023 hydrochloride.
-
公开(公告)号：US20220356261A1
公开(公告)日：2022-11-10
申请号：US17773935
申请日：2020-10-23
申请人： NOVARTIS AG
IPC分类号： C07K16/28 , A61K39/395 , A61K31/573 , A61P37/06
摘要： The present disclosure relates to methods for treating Sjögren's Syndrome disease using therapeutically effective doses of anti-BAFFR antibody, such as ianalumab.
-
公开(公告)号：US20240239911A1
公开(公告)日：2024-07-18
申请号：US18558730
申请日：2022-05-03
申请人： NOVARTIS AG
CPC分类号： C07K16/2878 , A61K9/0019 , A61P37/06 , A61K2039/505 , A61K2039/545 , C07K2317/565
摘要： The present disclosure relates to methods for treating Lupus Nephritis (LN) using an anti-BAFFR antibody or binding fragment thereof, e.g., ianalumab. Also disclosed herein are anti-BAFFR antibodies or binding fragments thereof, e.g., ianalumab, for treating LN patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.
-
公开(公告)号：US20240228644A1
公开(公告)日：2024-07-11
申请号：US18558729
申请日：2022-05-03
申请人： NOVARTIS AG
IPC分类号： C07K16/28 , A61K31/519 , A61K31/52 , A61K31/5377 , A61K31/573 , A61K31/7056 , A61K39/395 , A61P37/06
CPC分类号： C07K16/2878 , A61K31/519 , A61K31/52 , A61K31/5377 , A61K31/573 , A61K31/7056 , A61K39/3955 , A61P37/06 , C07K2317/21
摘要： The present disclosure relates to methods for treating Systemic Lupus Erythematosus (SLE) using an anti-BAFFR antibody or binding fragment thereof, e.g., ianalumab. Also disclosed herein are anti-BAFFR antibodies or binding fragments thereof, e.g., ianalumab, for treating SLE patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.
-
-
-
搜索结果
4 条记录 (耗时 0.012 秒)
